ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2025
The First-in-Man Technique of Drug Eluting and Perfusion Therapy for Left Main Coronary Artery Disease.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundTreating ostial left circumflex artery (LCx) lesions in percutaneous coronary intervention (PCI) for left main disease (LMD) remains a challenge. Despite recent recommendations for the use of drug-coated balloon (DCB) in this lesion, there are concerns about crossover-stenting from the left main trunk (LMT) to the left anterior descending artery (LAD). Specifically, isolated DCB treatment for the ostial LCx lesion may induce carina shift, while conventional kissing balloon technique (C-KBT) with a standard balloon and a DCB may prolong LMT occlusion, leading to hemodynamic instability.
objectivesThis study aimed to evaluate the safety and feasibility of a novel double-effect KBT (W-KBT) using a perfusion balloon (PB) for the LMT-LAD and a DCB for the LMT-LCx, allowing prolonged inflation while maintaining coronary perfusion.
methodsThis single-center prospective study enrolled consecutive patients with de-novo LMD and ostial LCx lesions, requiring crossover-stenting from the LMT to the LAD followed by proximal optimization technique and C-KBT. After confirming optimal PCI, W-KBT was performed.
resultsAmong 12 enrolled patients (mean age 73.8 ± 7.2, 91.7% men), procedural success, defined as device delivery and W-KBT time ≥ 30 s, was achieved in all cases via the transradial approach. W-KBT inflation-time was consistently 60 s; ST changes occurred in 50% (no ST-elevation); mean ST-change time was 41.2 ± 7.1 s; mean delta-blood pressure was -13.7 ± 11.4 mmHg; mean delta-heart rate was -3.4 ± 5.9 bpm; and no inotropes or mechanical cardiac support were needed.
conclusionWithin the limited sample size of this pilot study, the safety and feasibility of the first-in-man W-KBT were suggested. SUMMARY: This pilot study evaluated the safety and feasibility of a novel double-effect kissing balloon technique (W-KBT) in percutaneous coronary intervention for left main coronary artery disease, realized by the combined use of a perfusion balloon and a drug-coated balloon. Among 12 patients, device delivery was successful via a transradial approach using a 7 Fr guiding catheter. The W-KBT was maintained for 60 s without hemodynamic instability, providing adequate drug application to the ostial left circumflex artery lesion. Furthermore, no ST-elevation or periprocedural myocardial infarction was observed, highlighting the safety and feasibility of this technique.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.